 |
 |
 |
||||||
 |
||||||||
 |
 |
 |
 |
|||||
 |
 |
 |
|
|||||
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
2006 Press Archive | |
|
2005 Press Archive | |
|
2004 Press Archive | |
|
2002 Press Archive | |
|
2001 Press Archive | |
|
2000 Press Archive | |
|
|
|
Sangamo BioSciences Announces Second-Quarter 2003 Teleconference
RICHMOND, Calif., July 21 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its second-quarter 2003 financial results on Monday, July 28, 2003 after the market closes. The press release will be followed by a conference call at 2:00 p.m. PDT, which will be open to the public. During the conference call, the company will review the financial results and discuss other business matters.
The conference call dial-in numbers are 800-730-7991 for domestic callers and 706-634-7552 for international callers. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 5:00 p.m. PDT on July 28, 2003 to 9:00 p.m. PDT on August 4, 2003. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 1832550.
About Sangamo
Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company’s most advanced therapeutic development program involves the use of transcription factors for the treatment of peripheral vascular disease. Other therapeutics development programs are focused on cardiovascular disease, cancer and neuropathic pain. Sangamo’s proprietary technology enables the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene and fusing this to a suitable functional domain, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics and pharmaceutical discovery. Sangamo is also developing ZFP-restriction enzymes for use in targeted gene correction for the treatment and potential cure of monogenic disease. For more information about Sangamo, visit the company’s web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo’s ZFP Therapeutic programs. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. See the company’s SEC filings, and in particular, the risk factors described in the company’s Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
07/21/2003
CONTACT: Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc.,
+1-510-970-6000, ext. 271, ewolffe@sangamo.com
Web site: http://www.sangamo.com
(SGMO)
back to top
|
Contact |  |
Careers | |
Site Map | |
Legal | |
Glossary | |
|
|
|
|
|
|
|